Pluristem Life Systems, Inc. (OTCBB: PLRS) biotechnology company is dedicated to the commercialization of allogeniec cell therapy products for the treatment of severe blood, cardiovascular and autoimmune disorders. The first product planned by the company is dedicated to resolving the global shortfall of matched tissue for bone marrow transplantation by improving the engraftment of umbilical cord blood (UCB). The Company owns GMP early stage facilities and an animal house to conduct research, development and manufacturing of its products.

Pluristem has discovered and patented a process to grow and expand Adult Mesenchymal and Hematopoietic Stem Cells (MCS, HSC). Cell expansion is executed in an environment that mimics natures microstructure of bone marrow and does not include the supplemented growth factors of cytokines. It is for this reason that Pluristem's Technology is to the best of our knowledge the most efficient and safe way to grow Mesenchymal and Hematopoietc stem cells on a production scale for cell therapy products. The first product targets a critical global shortfall of matched tissue for bone marrow transplantation (BMT).

Pluristem’s pipeline of products begins as adherent stromal cells (ASCs) that are derived from the human placenta, an organ that has traditionally been considered medical waste after childbirth and a non-embryonic, non-controversial source of cells. Pluristem’s placental-derived ASCs are then grown in a unique and proprietary three-dimensional (3D) microenvironment, termed the Pluristem PluriX™ 3D bioreactor, without the addition of growth factors or other adulterants. The ASCs derived from this process are called PLacental eXpanded or PLX cells. Pluristem believes these cells' efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, these PLX cells are immune-privileged and possess immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations. The PLX cells are stored “ready to use” with no histocompatibility matching required.

Pluristem is an American public company that employs 29 talented, experienced individuals including four PhDs and an MD. The Company has an office in Colorado with headquarters housing its research and development and FDA good manufacturing practices (GMP)-approved facilities in Haifa, Israel.